14.38

2.79% 0.39

After Hours: 14.39 0.010 +0.07%

Dr Reddys Laboratories Ltd Adr (RDY)

Overview News Price History Option Chain Why RDY Down? Discussions Forecast Stock Split Dividend History

Dr Reddys Laboratories Ltd Adr stock is traded at $14.38, with a volume of 2.18M. It is up +2.79% in the last 24 hours and up +10.36% over the past month. Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Previous Close:

$13.99

Open:

$14.16

24h Volume:

2.18M

Relative Volume:

0.86

Market Cap:

$11.97B

Revenue:

$3.81B

Net Income/Loss:

$485.75M

P/E Ratio:

24.48

EPS:

0.5873

Net Cash Flow:

$175.50M

1W Performance:

-5.70%

1M Performance:

+10.36%

6M Performance:

+3.75%

1Y Performance:

-3.36%

1-Day Range:

$14.16

$14.48

1-Week Range:

$13.95

$15.67

52-Week Range:

$12.19

$15.67

Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile

Name

Dr Reddys Laboratories Ltd Adr

Sector

Healthcare (1098)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

Address

Employee

27,527

Twitter

@drreddys

Next Earnings Date

2026-07-22

Latest SEC Filings

RDY's Discussions on Twitter

Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RDY Dr Reddys Laboratories Ltd Adr	14.38	12.07B	3.81B	485.75M	175.50M	0.5873
TAK Takeda Pharmaceutical Co Adr	16.77	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.82	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.64	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	74.80	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	555.91	23.00B	3.17B	1.29B	1.01B	27.09

Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-23-26	Downgrade	Goldman	Neutral → Sell
Jun-05-25	Upgrade	HSBC Securities	Hold → Buy
Dec-19-24	Downgrade	Nomura	Buy → Neutral
Jan-11-24	Downgrade	Jefferies	Buy → Underperform
Aug-29-23	Downgrade	HSBC Securities	Buy → Hold
May-18-23	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-17-23	Upgrade	BofA Securities	Neutral → Buy
Jan-30-23	Initiated	JP Morgan	Underweight
Nov-14-22	Downgrade	Credit Suisse	Neutral → Underperform
Jan-03-22	Resumed	BofA Securities	Neutral
Jul-27-21	Downgrade	Credit Suisse	Outperform → Neutral
Feb-02-21	Upgrade	Barclays	Equal Weight → Overweight
Sep-18-20	Upgrade	BofA Securities	Neutral → Buy
Sep-18-20	Upgrade	Investec	Sell → Hold
Jan-28-20	Downgrade	CLSA	Buy → Outperform
Jan-27-20	Downgrade	CLSA	Buy → Outperform
Jan-09-20	Upgrade	Citigroup	Sell → Buy
Nov-04-19	Downgrade	BofA/Merrill	Buy → Neutral
Sep-04-19	Upgrade	Credit Suisse	Underperform → Outperform
Jul-01-19	Upgrade	Macquarie	Neutral → Outperform
Jun-20-19	Initiated	Deutsche Bank	Hold
Jun-11-19	Initiated	Barclays	Equal Weight
May-20-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-19-19	Upgrade	CLSA	Outperform → Buy
Jan-17-19	Downgrade	Citigroup	Neutral → Sell
Sep-21-17	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-31-17	Upgrade	CLSA	Underperform → Outperform
Jul-28-17	Downgrade	CLSA	Underperform → Sell
Jul-27-16	Downgrade	HSBC Securities	Hold → Reduce
Jul-27-16	Downgrade	Jefferies	Hold → Underperform
Feb-10-16	Upgrade	Credit Agricole	Underperform → Buy
Nov-10-15	Downgrade	Citigroup	Buy → Neutral

View All

Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News

Jun 30, 2026

Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Jun 30, 2026

Jun 27, 2026

Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade

Jun 27, 2026

Jun 26, 2026

RDDA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView

Jun 26, 2026

Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers - AD HOC NEWS

Jun 26, 2026

Enterprise value to EBIT forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView

Jun 26, 2026

Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR - TradingView

Jun 26, 2026

Dr. Reddy’s files 2026 annual report with the SEC - Stock Titan

Jun 26, 2026

659157 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 22, 2026

Form 6K DR REDDYS LABORATORIES LTD For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

Form 6K Kinross Gold Corp For: 22 June By Investing.com - Investing.com Nigeria

Jun 22, 2026

Dr. Reddy’s (NYSE: RDY) allots 6,730 ESOP shares to employees - Stock Titan

Jun 22, 2026

Jun 20, 2026

Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - AD HOC NEWS

Jun 20, 2026

Jun 18, 2026

Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS

Jun 18, 2026

Jun 17, 2026

RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill

Jun 17, 2026

Jun 16, 2026

Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - AD HOC NEWS

Jun 16, 2026

Jun 15, 2026

Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - Ad-hoc-news.de

Jun 15, 2026

Jun 09, 2026

Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - AD HOC NEWS

Jun 09, 2026

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Jun 09, 2026

Jun 05, 2026

With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar

Jun 05, 2026

Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan

Jun 05, 2026

Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn

Jun 05, 2026

May 31, 2026

Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK

May 31, 2026

Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com India

May 31, 2026

May 20, 2026